Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of initial treatment with tofogliflozin or metformin on pancreatic beta-cell function in drug-naive type 2 diabetes
jRCTs011230006Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Tofogliflozin with Metformin (2 arms). Primary endpoint: Change in disposition index at 4 weeks. Started Jun 2023; status: completed.
02
Drugs
tofogliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs011230006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011230006.